These authors imply that RTK-AXL plays a critical role in both intrinsic and acquired resistance to standard GBM therapy, and monitoring their expression and shedding products as indicators of therapy resistance and tumor progression could be a promising approach for individualized therapy. Glioblastoma (GBM) remains the most common and aggressive malignant primary brain tumor. 10.3390/ijms222212150 9 Seifert C., Balz E., Herzog S., Korolev A., Gaßmann S., Paland H., Fink M.A., Grube M., Marx S., Jedlitschky G. PIM1 Inhibition Affects Glioblastoma Stem Cell Behavior and Kills Glioblastoma Stem-like Cells. The authors reported that sst5TMD4 was significantly overexpressed in human GBM tissues and was notably associated with poor overall survival and recurrent tumors in GBM patients. [Extracted from the article]